跳至主要内容
临床试验/IRCT20100127003200N6
IRCT20100127003200N6招募中3 期

Safety and efficacy of Anti-Thymocyte Globulin (Zist Kowsar Pharmaceutical Company) in comparison with Anti-Thymocyte Globulin (Genzyme) for immunosuppressive induction therapy in adults with renal transplantation: A phase III, randomized, parallel, single blind , non-inferiority design

Kowsar Biotechnology company0 个研究点目标入组 129 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
129

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Age >18 years (donor age >= 5) for recipient
  • ability and willingness to sign the informed consent
  • Reception of kidney from cadaver OR second graft (already rejected a kidney more than 6-12 month ago) OR indication for receiving the investigated drug

排除标准

  • Positive history of polyclonal Anti-T-Cell therapy
  • Known allergy to Rabbit proteins
  • Positive history of malignancy in 2 years( excluding stem cell , squamous cell, bladder malignancies and asymptomatic invasive papillary renal cell cancer with less than 5 cm size)
  • Lactating mother
  • Willingness to pregnancy and not using a safe contraceptive method
  • Positive serology for: HTLV, HIV or HBV

研究者

发起方
Kowsar Biotechnology company

相似试验